Medical Library | Shanghai Pediatric and Family Medicine Innovation Series
Shanghai Jiao Tong University-affiliated Xinhua Hospital is a major center for child development, pediatric endocrinology and genetics, pediatric urology, congenital heart disease, fetal medicine, and high-risk pregnancy care. Its 2025–2026 programs range from accessible non-invasive neuromodulation to first-in-country rare-disease gene therapy, pediatric sacral neuromodulation, biodegradable cardiac devices, and integrated fetal medicine.
This Medical Library review summarizes five representative teams and directions based on the information provided. It also explains how CMCS can help international families prepare medical records and communicate with the appropriate pediatric, genetic, cardiac, urology, or fetal-medicine team.
1. Developmental and Behavioral Pediatrics: Scalable Neuromodulation for Autism
Lead: Professor Li Fei
Focus: Early intervention for autism spectrum disorder and neuromodulation.
The team studied accelerated continuous theta-burst stimulation, or a-cTBS, as an intervention for autism. The randomized, sham-controlled multicenter trial was published in The BMJ in May 2026 and was described as the largest neuromodulation randomized controlled trial in the international autism field.
The program also collaborated with Professor Qiu Zilong's team on a base-editing approach, TeABE, for CHD3-related disease. The work was reported in Nature in February 2026.
Non-invasive neuromodulation may be attractive because it can potentially be delivered more broadly than implanted devices or highly specialized surgery. However, families should ask which symptoms were measured, how long the benefit lasted, what sham control was used, whether the child was receiving behavioral therapy at the same time, and whether the approach is approved or still part of a research protocol.
The CHD3 base-editing work represents a different stage of innovation. A molecular correction strategy may be scientifically important without being ready for routine pediatric use. Families should confirm whether the evidence comes from cell or animal models, an early clinical study, or an approved treatment.
For broader background on neurotechnology and neuromodulation, see our Brain–Computer Interface Therapy in Shanghai guide.
Clinical profile: A pediatric program combining accessible non-invasive neuromodulation with advanced genetic research for biologically defined developmental disorders.
2. Pediatric Endocrinology, Genetics, and Metabolic Disease: Bringing Rare-Disease Therapies to Children
Lead: Professor Yu Yongguo
Focus: Rett syndrome, achondroplasia, Alagille syndrome, and other pediatric rare diseases.
Key 2025–2026 milestones
- Rett syndrome: The first reported domestic administration of GCB-002, an AAV-MECP2 gene-therapy program, was completed in February 2025.
- Achondroplasia: The first reported domestic use of vosoritide was completed in April 2025.
- Alagille syndrome: An antisense-oligonucleotide therapy was reported as the world's first ASO drug for Alagille syndrome in August 2025.
Rare-disease care often requires two tracks at the same time. Families may need access to an imported therapy through a temporary or special pathway while also participating in domestic clinical research and follow-up. This combination of overseas treatment access and local gene-therapy investigation is described as one of the program's distinguishing features.
Gene therapy and ASO treatment require careful confirmation of the molecular diagnosis. Families should ask whether genetic testing has identified the exact pathogenic variant, whether the treatment is approved or investigational, how long-term safety will be monitored, and what follow-up is required for liver function, immune response, growth, development, and organ-specific complications.
Vosoritide is also not appropriate for every child with short stature or skeletal dysplasia. Treatment timing, open growth plates, age, genotype, growth pattern, and specialist monitoring all matter.
Clinical profile: A rare-disease program using both special access to overseas therapies and domestic gene-therapy clinical research.
3. Pediatric Urology: Sacral Neuromodulation for Bladder Dysfunction
Team: Pediatric urology team
Focus: Childhood voiding disorders and neurogenic bladder.
On September 15, 2026, the program completed its 100th pediatric sacral neuromodulation procedure and was described as the first pediatric center in China to reach 100 cases.
Sacral neuromodulation delivers electrical stimulation to nerves involved in bladder and pelvic-floor control. It may be considered for selected children with severe bladder dysfunction when behavioral treatment, medication, catheterization, or other approaches have not provided adequate control.
Patient selection requires a clear diagnosis. Urinary symptoms may result from neurogenic bladder, congenital urinary-tract abnormalities, dysfunctional voiding, spinal disease, constipation, infection, or behavioral factors. Families should ask what testing was performed, whether urodynamics are required, what device and programming schedule will be used, and how growth may affect future revision or replacement.
The goal is not only fewer accidents. It may also include protecting kidney function, reducing urinary infections, improving continence, supporting school participation, and reducing caregiver burden.
Clinical profile: A pediatric urology program filling a treatment gap for children with difficult voiding disorders and neurogenic bladder.
4. Pediatric Cardiology and Cardiothoracic Surgery: From Fetal Care to the Delivery Room
Leads: Professors Ding Fangbao, Lu Yanan, and Wang Lei
Focus: Complex congenital heart disease and fetal intrauterine treatment.
The program is described as covering an integrated pathway from fetal diagnosis and intrauterine treatment to delivery-room surgery and pediatric congenital-heart repair.
Key 2025–2026 milestone
A self-expanding, single-rivet, bioresorbable atrial septal defect occluder received NMPA approval in June 2026. It was described in the supplied material as the world's first bioresorbable occluder with self-expanding and shape-recovery performance.
A bioresorbable occluder is designed to provide structural support during healing and then gradually disappear, potentially reducing the long-term presence of a permanent implant. Families should confirm the exact approved age range, defect size, anatomical criteria, imaging requirements, follow-up schedule, and evidence for complete resorption and long-term safety.
Fetal and neonatal heart care is particularly time-sensitive. The treatment plan may involve fetal echocardiography, genetic counseling, delivery planning, neonatal intervention, surgery, and long-term developmental follow-up. Our related pediatric cardiology and congenital heart disease specialist profile provides additional background.
Clinical profile: A full-chain pediatric cardiac model linking fetal assessment, delivery-room management, biodegradable devices, and congenital-heart surgery.
5. Obstetrics and Prenatal Diagnosis: Building a Fetal Medicine Hospital
Leads: Professors Wang Xipeng and Wang Lei
Focus: High-risk pregnancy and fetal structural abnormalities.
The hospital formally began planning a dedicated “fetal hospital” in January 2025. In October 2025, the team reported the birth of a baby after a three-generation IVF strategy intended to block transmission of a rare disease.
Fetal medicine is increasingly multidisciplinary. A complete pathway may involve preconception counseling, carrier testing, family genetic analysis, IVF with preimplantation genetic testing, fetal ultrasound, fetal MRI, invasive prenatal diagnosis when needed, maternal-fetal medicine, neonatology, pediatric surgery, and long-term child development follow-up.
Three-generation IVF or other genetic strategies require careful genetic counseling. Families should confirm the inheritance pattern, the exact variant, the limitations of embryo testing, the possibility of mosaicism or misdiagnosis, and the need for prenatal confirmation. No genetic strategy reduces risk to zero.
Our Fertility Treatment in Shanghai: IVF Options for International Patients guide provides related information for families considering assisted reproduction.
Clinical profile: An institutional effort to build fetal medicine as a coordinated pathway from genetic prevention and prenatal diagnosis to fetal and neonatal treatment.
6. How to Interpret These Pediatric Innovations
The five programs address different stages of pediatric care:
- Early developmental intervention: non-invasive neuromodulation and genetic research for autism-related conditions.
- Rare-disease treatment: gene therapy, ASO therapy, and imported targeted medicines.
- Functional urology: sacral neuromodulation for difficult bladder disorders.
- Congenital heart care: biodegradable devices and fetal-to-neonatal treatment pathways.
- Prevention and prenatal medicine: genetic counseling, IVF, fetal diagnosis, and high-risk pregnancy management.
Families should distinguish between a peer-reviewed study, an approved device, a first clinical administration, an investigator-initiated trial, and routine standard care. Children's age, growth, organ development, genetic status, and ability to cooperate with testing can all affect treatment decisions.
7. How CMCS Helps International Families Communicate with Pediatric Specialists
For an international family seeking pediatric neurology, rare-disease, urology, cardiology, fetal-medicine, or fertility care in Shanghai, the first step is to match the clinical question with the right specialist team. China Medical Concierge Shanghai (CMCS) is a health management and medical coordination service that helps families connect with specialist doctors and hospital resources in Shanghai. CMCS is not a hospital and does not independently diagnose or prescribe treatment.
Before a consultation, CMCS can help organize genetic reports, developmental assessments, brain and heart imaging, fetal ultrasound, prenatal records, urodynamics, kidney-function tests, medication history, previous procedures, rehabilitation records, and the family's main concerns. For overseas families, the records can be arranged into a concise English medical summary for the pediatric specialist.
CMCS can help families prepare focused questions such as:
- Is the proposed therapy approved for this child's exact diagnosis, age, genetic variant, and treatment stage?
- Is the treatment a standard option, an imported medicine, an investigator-initiated trial, or an early research program?
- What genetic confirmation, imaging, developmental assessment, or urodynamic testing is required?
- What are the short-term and long-term safety risks, including effects on growth, fertility, immunity, cognition, and organ function?
- For fetal or reproductive care, what are the limitations of embryo testing and prenatal diagnosis?
- What follow-up, rehabilitation, device programming, surgery, or emergency support will the child need?
During the consultation, CMCS can assist with appointment coordination, medical interpretation, communication between the family and the care team, and clarification of the doctor's recommendations. Afterward, a case manager can help organize the proposed next steps, identify additional tests or records, clarify the follow-up schedule, and coordinate further communication with the hospital.
The final treatment decision must be made by the family and the treating medical team. CMCS does not independently select a gene therapy, device, surgery, fertility pathway, or clinical trial. Its role is to help the family bring complete information to the right specialist and ensure that evidence, eligibility, risks, alternatives, access, and monitoring are discussed clearly.
To learn more about pediatric consultations and treatment coordination in Shanghai, contact CMCS:
Email: contract@medicalsh.com
WhatsApp: Contact CMCS on WhatsApp
Website: medicalsh.com
Conclusion
The Xinhua Hospital teams reviewed here show how pediatric medicine is moving toward earlier intervention, molecular diagnosis, targeted rare-disease treatment, neuromodulation, biodegradable devices, and integrated fetal-to-neonatal care.
For families, the goal is not to pursue every new technology, but to identify the option that fits the child's diagnosis, age, developmental stage, genetic profile, anatomy, health status, and family priorities. This article was prepared from the team and program information provided for editorial use. Research findings, product names, approval status, clinical claims, and treatment access should be confirmed through the hospital, research team, regulatory authorities, and formally published studies. This article is for medical education only and is not individualized medical advice.
0 comments